Recombinant VSV Vectors for HIV Broadly Neutralizing Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for developing HIV vaccines have not efficiently elicited broadly neutralizing antibodies, as existing approaches fail to effectively present immunogens that trigger broad specificity neutralization.
Innovation Solution
The use of recombinant vesicular stomatitis virus (VSV) vectors, where the VSV surface glycoprotein G is replaced or modified to harbor HIV Env epitopes, particularly from the gp41 membrane-proximal external region, to create chimeric proteins that can be recognized by broadly neutralizing antibodies, and subjected to serial passage to enhance immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HIV vaccine approaches are used, then vaccine development can proceed with current methods, but broadly neutralizing antibodies are not efficiently elicited
Solution Approach 1:
The patent uses a recombinant VSV vector as an intermediary carrier to deliver HIV immunogens. The VSV vector serves as a mediator between the HIV antigens and the host immune system, enabling efficient presentation of gp120 and gp41 epitopes that trigger broadly neutralizing antibody responses, while maintaining a relatively simple vaccine administration approach
Solution Approach 2:
The patent creates composite viral vectors by combining VSV structural components with HIV immunogenic components. The recombinant VSV contains VSV genomic elements for replication and packaging, plus HIV-derived immunogens (gp120, gp41, or chimeric proteins) inserted into the VSV genome, forming a composite structure that leverages both viruses' properties to achieve broad neutralization
2Reliability
If VSV surface glycoprotein G is replaced or modified to harbor HIV Env epitopes, then chimeric proteins can be recognized by broadly neutralizing antibodies, but the viral vector structure becomes more complex
Solution Approach 1:
The patent applies local quality by making targeted modifications to specific regions of the VSV genome rather than completely redesigning the virus. The HIV immunogens are inserted at specific locations in the VSV genome (replacing or modifying the G gene), allowing the rest of the VSV structure to remain intact and functional for replication and packaging
Solution Approach 2:
The recombinant VSV vector is designed to perform multiple functions: it maintains VSV's ability to replicate and package viral particles, while simultaneously presenting HIV immunogens to elicit neutralizing antibodies. The single recombinant vector accomplishes both viral propagation and vaccine antigen delivery functions
3Reliability
If serial passage is used to enhance immunogenicity, then the humoral immune response capability is improved, but the time required for vaccine development increases
Solution Approach 1:
The patent performs preliminary optimization of the VSV vector through serial passage in cell cultures before clinical use. This preliminary action in controlled laboratory conditions enhances the immunogenicity of the vector and ensures optimal performance, so that subsequent vaccine administrations can achieve maximum immune response capability without requiring additional time-consuming optimization steps
Data Source
AI summary
The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.